Annals of the New York Academy of Sciences

Cover image for Annals of the New York Academy of Sciences

December 1999

Volume 886 ANTICANCER MOLECULES: STRUCTURE, FUNCTION, AND DESIGN

Pages xi–xii, 1–299

  1. Frontmatter

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
    1. Introduction (pages xi–xii)

      HIROSHI MARUTA

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09394.x

  2. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
    1. Telomerase: A Target for Anticancer Therapy (pages 1–11)

      SERGE P. LICHTSTEINER, JANE S. LEBKOWSKI and ALAIN P. VASSEROT

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09395.x

    2. A Paradigm for Cancer Treatment Using the Retinoblastoma Gene in a Mouse Model (pages 12–22)

      ALEXANDER YU. NIKITIN, DANIEL J. RILEY and WEN-HWA LEE

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09396.x

  3. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
    1. Cytoskeletal Tumor Suppressors That Block Oncogenic RAS Signaling (pages 48–57)

      HIROSHI MARUTA, HONG HE, ANJALI TIKOO and MSA NUR-E-KAMAL

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09399.x

  4. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
    1. Antiangiogenic Domains Shared by Thrombospondins and Metallospondins, a New Family of Angiogenic Inhibitors (pages 58–66)

      M. LUISA IRUELA-ARISPE, FRANCISCA VÁZQUEZ and MARIA ASUNCIÓN ORTEGA

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09400.x

    2. Immunotherapy of Cancer (pages 67–72)

      ELIZABETH M. JAFFEE

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09401.x

    3. Intracellular Signaling of the TGF-β Superfamily by Smad Proteins (pages 73–82)

      MASAHIRO KAWABATA, TAKESHI IMAMURA, HIROFUMI INOUE, JUN-ICHI HANAI, AYAKO NISHIHARA, AKI HANYU, MASAO TAKASE, YASUHIRO ISHIDOU, YOSHIYUKI UDAGAWA, EIICHI OEDA, DAISUKE GOTO, KEN YAGI, MITSUYASU KATO and KOHEI MIYAZONO

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09402.x

  5. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
  6. Article: Part IV. Anticancer Drugs

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
  7. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
    1. Azatyrosine: Mechanism of Action for Conversion of Transformed Phenotype to Normal (pages 109–121)

      YOSHIAKI MONDEN, FUMIE HAMANO-TAKAKU, NOBUKO SHINDO-OKADA and SUSUMU NISHIMURA

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09406.x

    2. SCH 51344, An Inhibitor of RAS/RAC-Mediated Cell Morphology Pathway (pages 122–131)

      C. CHANDRA KUMAR, KAZUMASA OHASHI, KYOKO NAGATA, AMY WALSH, DAFNA BAR-SAGI and KENSAKU MIZUNO

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09407.x

  8. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
  9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers

    1. Top of page
    2. Frontmatter
    3. Anticancer Moleculesa: Structure, Function, and Design: Part I. Nuclear Proteins
    4. Anticancer Moleculesa: Structure, Function, and Design: Part II. Cytoplasmic Proteins
    5. Anticancer Moleculesa: Structure, Function, and Design: Part III. Extracellular Proteins
    6. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    7. Article: Part IV. Anticancer Drugs
    8. Anticancer Moleculesa: Structure, Function, and Design: Part IV. Anticancer Drugs
    9. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting
    10. Anticancer Moleculesa: Structure, Function, and Design: Part V. DNA or Peptide Delivery/Targeting: Poster Papers
    1. In Vitro Evaluation of a Novel 2,6,9-Trisubstituted Purine Acting As a Cyclin-Dependent Kinase Inhibitor (pages 180–182)

      NICOLE GIOCANTI, RAMIN SADRI, MICHEL LEGRAVEREND, ODILE LUDWIG, EMILE BISAGNI, SOPHIE LECLERC, LAURENT MEIJER and VINCENT FAVAUDON

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09411.x

    2. Selection of Genetic Suppressor Elements Conferring Resistance to DNA Topoisomerase II Inhibitors (pages 187–189)

      C. DELAPORTE, L. GROS, S. FREY, D. COCCARD, L. CAVAREC, A. DUBAR, A. GUDKOV and A. JACQUEMIN-SABLON

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09413.x

    3. BAP1, a Candidate Tumor Suppressor Protein That Interacts with BRCA1 (pages 191–194)

      DAVID E. JENSEN and FRANK J. RAUSCHER III

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09414.x

    4. Histone Deacetylase Inhibitor Activates the p21/WAF1/Cip1 Gene Promoter through the Sp1 Sites (pages 195–199)

      Y. SOWA, T. ORITA, S. HIRANABE-MINAMIKAWA, K. NAKANO, T. MIZUNO, H. NOMURA and T. SAKAI

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09415.x

    5. Melanoma Cell Lines Contain a Proteasome-Sensitive, Nuclear Cytoskeleton-Associated Pool of β-Catenin (pages 208–211)

      P. BONVINI, S.-G. HWANG, M. EL-GAMIL, P. ROBBINS, L. NECKERS and J. TREPEL

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09418.x

    6. Truncated Form of β-Catenin and Reduced Expression of Wild-Type Catenins Feature HepG2 Human Liver Cancer Cells (pages 212–216)

      GIUSEPPE CARRUBA, MELCHIORRE CERVELLO, MARIA D. MICELI, ROSARIA FARRUGGIO, MONICA NOTARBARTOLO, LUCREZIA VIRRUSO, LYDIA GIANNITRAPANI, ROBERTO GAMBINO, GIUSEPPE MONTALTO and LUIGI CASTAGNETTA

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09419.x

    7. Induction of Apoptosis by Gelsolin Truncates (pages 217–220)

      HISAKAZU FUJITA, PHILIP G. ALLEN, PAUL A. JANMEY, TOSHIFUMI AZUMA, DAVID J. KWIATKOWSKI, THOMAS P. STOSSEL and N. KUZUMAKI

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09420.x

    8. Expression of Matrix Metalloproteinases and Their Inhibitors in Human Brain Tumors (pages 236–239)

      RICHARD BÉLIVEAU, LOUIS DELBECCHI, EDITH BEAULIEU, NATHALIE MOUSSEAU, ZARIN KACHRA, FRANCE BERTHELET, ROBERT MOUMDJIAN and ROLANDO DEL MAESTRO

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09425.x

    9. Polysulfated Heparinoids Selectively Inactivate Heparin-Binding Angiogenesis Factors (pages 243–248)

      G. ZUGMAIER, R. FAVONI, R. JAEGER, N. ROSEN and C. KNABBE

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09427.x

    10. RPR 130401, a Nonpeptidomimetic Farnesyltransferase Inhibitor with in Vivo Activity (pages 249–251)

      P. VRIGNAUD, M. C. BISSERY, P. MAILLIET and F. LAVELLE

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09428.x

    11. Cellular Effects of a New Farnesyltransferase Inhibitor, RPR-115135, in a Human Isogenic Colon Cancer Cell Line Model System HCT-116 (pages 252–256)

      P. RUSSO, C. OTTOBONI, C. FALUGI, W. REINHOLD, J. F. RIOU, S. PARODI and P. M. O'CONNOR

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09429.x

    12. Isolation of Farnesyltransferase Inhibitors from Herbal Medicines (pages 261–264)

      BYOUNG-MOG KWON, SEUNG-HO LEE, MI-JEONG KIM, HYAE-KYEONG KIM and HWAN MOOK KIM

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09431.x

    13. Inhibition of Protein Tyrosine Kinase Activity by 1a-Docosahexaenoyl Mitomycin C (pages 269–272)

      MAYUMI SHIKANO, KENJIRO ONIMURA, HIDESUKE FUKAZAWA, SATOSHI MIZUNO, KAZUNAGA YAZAWA and YOSHIMASA UEHARA

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09433.x

    14. Peptides Mimicking Sialyl-Lewis A Isolated from a Random Peptide Library and Peptide Array (pages 276–279)

      INSUG O, THOMAS KIEBER-EMMONS, LASZLO OTVOS JR. and MAGDALENA BLASZCZYK-THURIN

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09435.x

    15. The Anti-RAS Cancer Drug MKT-077 Is an F-Actin Cross-Linker (pages 283–284)

      HIROSHI MARUTA, ANJALI TIKOO, RUSHDI SHAKRI and TADAO SHISHIDO

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09437.x

    16. Construction of a Cell-Permeable CDC42 Binding Fragment of ACK That Inhibits v-Ha-Ras Transformation (pages 285–288)

      M.S. A. NUR-E-KAMAL, M. M. QURESHI, J. M. KAMAL, W. MONTAGUE and H. MARUTA

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09438.x

    17. Rational Development of Cell-Penetrating High Affinity SH3 Domain Binding Peptides That Selectively Disrupt the Signal Transduction of Crk Family Adapters (pages 289–292)

      CHRISTIAN KARDINAL, GUIDO POSERN, JIE ZHENG, BEATRICE S. KNUDSEN, AMGEN PEPTIDE TECHNOLOGY GROUP, ISMAIL MOAREFI and STEPHAN M. FELLER

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09439.x

    18. Anti-HER2 Immunoliposomes for Targeted Drug Delivery (pages 293–296)

      K. HONG, D. B. KIRPOTIN, J. W. PARK, Y. SHAO, R. SHALABY, G. COLBERN, C. C. BENZ and D. PAPAHADJOPOULOS

      Article first published online: 6 FEB 2006 | DOI: 10.1111/j.1749-6632.1999.tb09440.x

SEARCH

SEARCH BY CITATION